Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
| ▸ | CCR4 | P51679 | 2/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5581980 | 0.81 | NQO2 (0.36) | CCR4NQO2EGFR | |
| SCHEMBL5582108 | 0.80 | PAK1 (0.39) | PDGFRBPDGFRANQO2EGFR | |
| SCHEMBL5581933 | 0.80 | CCR4 (0.33) | CCR4NQO2EGFR | |
| SCHEMBL5582323 | 0.80 | PDGFRB (0.42) | PDGFRBPDGFRACCR4CCR5PTPN11 | |
| SCHEMBL5581779 | 0.80 | PDE4B (0.39) | PDGFRBPDGFRA | |
| SCHEMBL5582165 | 0.79 | SIK1 (0.39) | CCR4NQO2EGFR | |
| SCHEMBL5581881 | 0.79 | KMO (0.37) | PDGFRBPDGFRACCR4NQO2EGFR | |
| SCHEMBL5582141 | 0.78 | NQO2 (0.41) | NQO2EGFRADORA2A | |
| SCHEMBL5582213 | 0.78 | EGFR (0.38) | CCR4NQO2EGFR | |
| SCHEMBL5582085 | 0.78 | CSNK2A2 (0.38) | CCR4NQO2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225308-A1 | 2-Amino Quinazoline Derivative | KYOWA HAKKO KOGYO CO.,LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| EP-1726584-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225308-A1 | 2-Amino Quinazoline Derivative | AGTR2, ABL1, AGTR1 | PDGFRB 2343/4885PDGFRA 2202/4885CCR4 3108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.